ArticleJNCI cancer spectrum2021
Diabetes and Prostate Cancer Outcomes in Obese and Nonobese Men After Radical Prostatectomy.
Article in JNCI cancer spectrum, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Assessing the relationship between cardiometabolic diseases and the risk of developing aggressive prostate cancer: a systematic review and meta-analysis.BMC cancer · 2025Pooled it
- Metabolic convergence of diabetes and prostate cancer: from dysglycemia to tumor microenvironment reprogramming.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Review
- Influence of diabetes mellitus and anti-diabetic drugs on pathophysiology and prognosis for primary prostate cancer.International urology and nephrology · 2026Review
- Mechanistic Link Between Glyoxalase 1 Expression and Methylglyoxal-Induced Oncogenic Stress in Prostate Cancer.bioRxiv : the preprint server for biology · 2025Article
- Interplay Between Type 2 Diabetes Susceptibility and Prostate Cancer Progression: Functional Insights intoDiagnostics (Basel, Switzerland) · 2025Article
- Improving drug repositioning with negative data labeling using large language models.Journal of cheminformatics · 2025Article
- Do Hispanic Puerto Rican men have worse outcomes after radical prostatectomy? Results from SEARCH.Cancer medicine · 2024Article
- Diabetes mellitus and prostate cancer risk: A mendelian randomization analysis.World journal of diabetes · 2023Article
- Diabetes and Prostate Cancer Outcomes in Men with Nonmetastatic Castration-Resistant Prostate Cancer: Results from the SEARCH Cohort.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023Article
- Metabolic syndrome is associated with aggressive prostate cancer regardless of race.Cancer causes & control : CCC · 2023Article
- Association between adiposity after diagnosis of prostate cancer and mortality: systematic review and meta-analysis.BMJ medicine · 2023Article
- Novel plasma exosome biomarkers for prostate cancer progression in co-morbid metabolic disease.Advances in cancer biology - metastasis · 2022Article
- Diabetes mellitus susceptibility with varied diseased phenotypes and its comparison with phenome interactome networks.World journal of clinical cases · 2022Review
- Review
- Association Between Obesity and Cancer Mortality: An Internal Medicine Outpatient Clinic Perspective.Journal of clinical medicine research · 2021Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 8 institutions in 1 country.
Funding
Abstract
Background: The link between diabetes and prostate cancer progression is poorly understood and complicated by obesity. We investigated associations between diabetes and prostate cancer-specific mortality (PCSM), castrate-resistant prostate cancer (CRPC), and metastases in obese and nonobese men undergoing radical prostatectomy (RP). Methods: We included 4688 men from the Shared Equal Access Regional Cancer Hospital cohort of men undergoing RP from 1988 to 2017. Diabetes prior to RP, anthropometric, and clinical data were abstracted from 6 Veterans Affairs Medical Centers electronic medical records. Primary and secondary outcomes were PCSM and metastases and CRPC, respectively. Multivariable-adjusted hazard ratios (adj-HRs) and 95% confidence intervals (CIs) were estimated for diabetes and PCSM, CRPC, and metastases. Adjusted hazard ratios were also estimated in analyses stratified by obesity (body mass index: nonobese <30 kg/m Results: Diabetes was not associated with PCSM (adj-HR = 1.38, 95% CI = 0.86 to 2.24), CRPC (adj-HR = 1.05, 95% CI = 0.67 to 1.64), or metastases (adj-HR = 1.01, 95% CI = 0.70 to 1.46), among all men. Interaction terms for diabetes and obesity were statistically significant in multivariable models for PCSM, CRPC, and metastases ( Conclusions: Diabetes was associated with increased risks of prostate cancer progression and mortality among obese men but not among nonobese men, highlighting the importance of aggressively curtailing the increasing prevalence of obesity in prostate cancer survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.